TECH|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q1'27 | $0.43 | - | - |
| Q3'26 | $0.53 | $0.53 | -0.8% |
| Q2'26 | $0.54 | $0.46 | -14.5% |
| Q3'25 | $0.42 | $0.42 | -0.4% |
| Q2'25 | $0.50 | $0.53 | +5.8% |
| Q1'25 | $0.51 | $0.56 | +10.4% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q1'27 | $298M | - | - |
| Q3'26 | $316M | $311M | -1.5% |
| Q2'26 | $317M | $296M | -6.5% |
| Q3'25 | - | $287M | - |
| Q2'25 | - | $317M | - |
| Q1'25 | - | $316M | - |
TECH|Monthly Returns
Market Data
TECH Stock Snapshot
- Market cap
- 11.32B
- P/E ratio
- 62.3
- Day range
- $71.79 – $72.29
- News sentiment
- 54/100 · Neutral
- Analyst target
- $70.73 (-2.2%)
- Consensus
- Hold · 24 analysts
Neither side has the upper hand on TECH right now, and the indicator set reflects that. Sector peers are worth watching - large caps in Healthcare tend to move together on rotation.
Reverse DCF
What growth is priced into TECH?
At today's price, Bio-Techne Corporation needs to grow free cash flow about 31.9% a year for the next 10 years to justify its valuation at a 10.01% cost of capital. Over its actual history it has compounded free cash flow at 6.5% a year, so the market is asking for 25.4 percentage points above its own delivered rate. On that basis TECH looks priced above what its own growth record supports.
- Implied FCF growth
- 31.9%
- Historical FCF CAGR
- 6.5%
- Growth gap
- +25.4 pts
- Verdict
- RICH
- Discount rate (WACC)
- 10.01%
- Beta
- 1.03
Behaviour On Record
What TECH's own history says about today's numbers
- Realized volatility (21d)
- 3.0% 0th pct
- Below its peak
- -46.4%
- vs 200-day average
- +17.8%
- Up days (1y)
- 53%
Bio-Techne Corporation is currently running 3.0% annualised volatility over the last 21 sessions. Measured against TECH's own 13 years of daily returns rather than a market-wide average, that is the 0th percentile — unusually subdued by its own history, against a typical reading of 26.7%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.
TECH is trading -46.4% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -21.4%, and the deepest was -43.1% in 2022. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.
Price sits +17.8% from its 200-day moving average. Against every other day in its history, that gap ranks at the 85th percentile — a wider gap than this stock usually carries. Over the past year TECH closed higher on 53% of sessions, and it is currently 2 sessions into a rising streak.
On September specifically: over 13 years of records, TECH finished the month higher 6 of 13 times, with a median return of -0.3% and an average of -0.7%. Its strongest month historically has been July at +4.7% on average, its weakest August at -3.0%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.
Overnight risk is measurable too: TECH has opened more than 2% away from the prior close in 149 of 3,267 sessions (4.6% of the time), with the largest gaps running +9.7% and -16.4%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.
All figures computed from 3,268 daily closes between 2013-09-16 and 2026-09-14, split-adjusted, recomputed daily. Percentiles are against TECH's own 13-year history, not a peer group or index.
Sector Rotation
Is money rotating into or out of TECH's sector?
Bio-Techne Corporation sits in the Health Care sector, currently ranked 3rd of 11 GICS sectors by relative-strength rotation score (leading). Within its narrower Biotechnology industry group, TECH ranks 3rd of 15 tracked industries, weakening.
- Sector rank
- #3 of 11
- Sector state
- Leading
- Sector rotation score
- 80
- Industry rank
- #3 of 15
Analyst Rating Changes
Are analysts turning bullish or bearish on TECH?
Wells Fargo most recently downgraded Bio-Techne Corporation to Equal-Weight on Aug 13, 2026 with a price target of $73 (from $62). Over the last 90 days, coverage has run 0 upgrades against 7 downgrades, a net bearish lean.
- Latest action
- Wells Fargo — Equal-Weight
- 90-day upgrades
- 0
- 90-day downgrades
- 7
- Net rating momentum
- -7
